Forget Bitcoin! I’d invest in these 2 FTSE 100 growth stocks today to make a million

I think these two FTSE 100 (INDEXFTSE:UKX) shares could offer better growth potential and value for money than Bitcoin.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

The doubling of Bitcoin’s price in 2019 means that many investors may be wondering whether to buy it. A significant problem with the virtual currency, however, is that its price is dependent upon investor sentiment rather than data. This means that it is not possible for an investor to deduce whether it offers good value for money at a specific time.

By contrast, there are a number of FTSE 100 shares that appear to be trading on low valuations at the present time. Here are two prime examples that could outperform Bitcoin over the long run, thereby improving your chances of making a million.

Hikma

Generic medicines specialist Hikma (LSE: HIK) recently reported an encouraging set of half-year results. They showed a rise in revenue of 7%, as well as an increase in core operating profit of 15%, when compared to the same half of the prior year.

The company continues to invest in its pipeline, increasing its investment in R&D during the period. This could strengthen its market position, and lead to improving financial performance.

Looking ahead, Hikma is expected to post a rise in its bottom line of 3% this year, with growth of 6% forecast for next year. Since it trades on a price-to-earnings (P/E) ratio of 17, it seems to lack a margin of safety at the present time. However, with demand for its products across a variety of markets likely to increase rapidly over the long run, it could be worthy of a premium valuation when compared to its FTSE 100 peers.

Therefore, now could be a good time to buy a slice of the business. Its relatively low correlation with the wider economy may mean that it offers resilient growth during an uncertain macroeconomic and political period.

Rolls-Royce

Another FTSE 100 share that could offer long-term growth potential is aerospace and defence company Rolls-Royce (LSE: RR). Its share price performance has been somewhat disappointing over recent months.

A key reason for this has been its disappointing updates. For example, its most recent trading update highlighted that it expects its financial performance for the full year to be towards the lower end of previous guidance. This is owing to the cost implications of issues faced within its civil aerospace division, where issues regarding its Trent 1000 engines are ongoing.

Despite this, the performance of the remainder of its business has improved over recent months. This means that it is on track to generate at least £1bn in free cash flow in 2020, which is in line with its overall plan.

Rolls-Royce currently trades on a price-to-earnings growth (PEG) ratio of just 0.4. This suggests that while its share price performance may continue to disappoint in the short run, it could produce capital growth over the long run that makes it a worthwhile purchase at the present time.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Peter Stephens owns shares of Hikma Pharmaceuticals and Rolls-Royce. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »